Dr. Jody Berry, Ph.D.

Chief Scientific Officer

Dr. Jody Berry, a distinguished scientific leader with over two decades of experience in infectious diseases, brings a wealth of expertise in diagnostics and therapeutics to his role at NOWDx. A recognized international expert in immunoassay development, antibody technology, and infectious diseases, Dr. Berry has over two decades of commercial, government and academic experience. Dr. Berry earned international recognition for his contributions to immunoassay development, antibody technology, and protein design. Notably, he was the first to develop neutralizing antibodies to type SARS-CoV-1 and prove that the receptor-binding domain (RBD) of the spike protein of SARS-CoV-1 is the protective domain for the virus. He utilized this experience nearly two decades later to develop groundbreaking products to help in the fight against SARS-CoV-2 (COVID-19).

Dr. Berry previously served as CSO and senior vice president of product development and innovation at Aspira Women's Health, an AI-based gynecological diagnostic company. He was also the CSO of OraSure Technologies, where he worked on the breakthrough development and EUA approval of the first integrated swab antigen test for COVID-19 (InteliSwab®) and the first 510(k) approved Oraquick® Ebola rapid antigen detection device. Dr. Berry was pivotal in securing over $100 million in funding for OraSure from BARDA, leading to manufacturing expansion and DPA Title 2, which continues to dominate OraSure's revenue. Dr. Berry has held other held leadership roles at BD Biosciences, Cangene Corporation and the National Microbiology Laboratory of the Public Health Agency of Canada.

Visit LinkedIn
Dr. Jody Berry, Ph.D. / Chief Scientific Officer